Clinical Response to Therapy in 228 Assessable Patients According to the Bcl-2 Breakpoint Site
| . | mcr (n = 27) . | MBR (n = 163) . | Germline (n = 38) . |
|---|---|---|---|
| Whole series | |||
| CR | 26 (96%) | 147 (90.5%) | 27 (71%) |
| PR | 1 (4%) | 15 (9%) | 10 (26%) |
| Failure | 0 | 1 (0.5%) | 1 (3%) |
| Stage IV disease | (n = 15) | (n = 104) | (n = 24) |
| CR | 14 (93%) | 92 (89%) | 17 (71%) |
| PR | 1 (7%) | 11 (10%) | 7 (29%) |
| Failure | 0 | 1 (1%) | 0 |
| . | mcr (n = 27) . | MBR (n = 163) . | Germline (n = 38) . |
|---|---|---|---|
| Whole series | |||
| CR | 26 (96%) | 147 (90.5%) | 27 (71%) |
| PR | 1 (4%) | 15 (9%) | 10 (26%) |
| Failure | 0 | 1 (0.5%) | 1 (3%) |
| Stage IV disease | (n = 15) | (n = 104) | (n = 24) |
| CR | 14 (93%) | 92 (89%) | 17 (71%) |
| PR | 1 (7%) | 11 (10%) | 7 (29%) |
| Failure | 0 | 1 (1%) | 0 |